Renalytix AI plc announces that that the Centers for Medicare and Medicaid Services has released the Final 2020 Clinical Laboratory Fee Schedule and has set.. Read More →

Renalytix AI plc announces that the Remuneration Committee agreed to issue options over a total of 50,000 ordinary shares of £0.0025 each in the capital.. Read More →

Renalytix AI plc, a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that it is participating in a London based event focused on.. Read More →

Renalytix AI plc, a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that Capital District Physicians’ Health Plan, Inc. .. Read More →

Renalytix AI plc announces the appointment of leading kidney investigator and clinician Dr. Chirag Parikh to the Renalytix board... Read More →

RenalytixAI plc announces CPT reimbursement code 0105U for its KidneyIntelX™ test in the United States.. Read More →

RenalytixAI plc announces at its annual general meeting held earlier today.. Read More →

RenalytixAI plc announces that it expects to appoint an additional non-executive director and healthcare industry veteran within the coming weeks.. Read More →

RenalytixAI plc announces that Centers for Medicare & Medicaid Services has published its preliminary determination for national Medicare pricing for the Company’s KidneyIntelX™ .. Read More →

RenalytixAI plc confirms that the Annual Report and Accounts for the period ended 30 June 2019.. Read More →

RenalytixAI plc announces its inaugural final results for the period ended June 30, 2019... Read More →

RenalytixAI plc investor briefing .. Read More →

RenalytixAI announces the expansion of its core investigator group for lead product KidneyIntelX™ for earlier identification of fast-progressing kidney disease in Type 2 diabetes... Read More →

RenalytixAI notifies the market for the purposes of DTR5.6.1R of the Transparency Directive... Read More →

RenalytixAI Expands Leadership Team with Focus on Reimbursement ahead of roll-out of artificial intelligence clinical in vitro diagnostic KidneyIntelX ™ .. Read More →

New announcement for investors.. Read More →

New announcement for investors.. Read More →

Renalytix AI welcomes US Administration’s dedication to advancing American kidney health.. Read More →

Renalytix AI plc announces that in a multi-centre cohort of Type 2 diabetes patients, the KidneyIntelX™ algorithm has met or exceeded required performance targets.. Read More →

Renalytix AI plc announces that the results are part of a continuing research programme from the FractalDx kidney transplant diagnostic portfolio.. Read More →

Renalytix AI plc announces that the American Medical Association has granted a CPT® Proprietary Laboratory Analyses Code for KidneyIntelX™.. Read More →

Renalytix AI plc announces announces positive study results have been published in the Journal of Clinical Investigation (JCI) Insight... Read More →

Renalytix AI plc announces announces that its in-vitro diagnostic manufacturing programme has reached a critical development milestone for the production materials used to measure blood-based.. Read More →

RenalytixAI announces announces that the New York State Department of Health has issued a Clinical Laboratory Improvement Amendment (CLIA) .. Read More →

Renalytix AI plc announces the expansion of the core investigator group supporting clinical and regulatory pathways for FractalDx, a portfolio of advanced diagnostic and prognostic.. Read More →

Renalytix AI plc announces a collaboration with University Medical Center Groningen (UMCG), Netherlands, to evaluate KidneyIntelX™ across over 3,500 patients... Read More →

Renalytix AI plc announces that it has been granted Breakthrough Device designation by the U.S. FDA, for its lead diagnostic, KidneyIntelX™. .. Read More →

EKF Diagnostics Holdings notes the announcement by Renalytix AI plc that on 26 April 2019 EKF Diagnostics plc acquired 100,074 ordinary RenalytixAI shares of £0.0025.. Read More →

The Company was informed that today, Christopher Mills, a non-executive director, completed the purchase of 3,168 ordinary shares. .. Read More →

TR-1: Standard form for notification of major holdings - April 2019.. Read More →

Renalytix AI plc announces publication of results generated by a confirmation study... Read More →

Renalytix AI plc announces its inaugural unaudited interim results for the six months ended 31 December 2018... Read More →

Investigators include leading transplant clinicians from Emory University, the University of Manitoba, the Westmead Hospital Sydney, and Icahn School of Medicine at Mount Sinai... Read More →

Renalytix AI announces that it will host investor briefings focused on AI-enabled diagnostics and kidney disease on Monday 25 March 2019.. Read More →

Renalytix AI announces the appointment of Stifel as the Company’s nominated adviser and joint broker with immediate effect. N+1 Singer will continue to act as.. Read More →

Renalytix AI announces the completion of a joint venture partnership agreement with AKESOgen, an industry-leading commercial laboratory facility and provider of clinical trial precision medicine services located in.. Read More →

Company Adds Clinical and Data Security Expertise to Support KidneyIntelX Clinical Validation, Software and Regulatory Programmes.. Read More →

Validation study to assess approximately 5,000 patients with participation from a multi-center group of leading U.S. investigators.. Read More →

This announcement relates solely to ordinary shares in the Company which were distributed to certain qualifying shareholders owning EKF Diagnostic Holdings plc shares prior to.. Read More →

Renalytix AI announces the exercise of its option for the exclusive license from the Icahn School of Medicine at Mount Sinai of a portfolio of.. Read More →

The Company was informed that today, Christopher Mills, a non-executive director, completed the purchase of 3,168 ordinary shares. .. Read More →

Renalytix AI notes the announcement today by EKF Diagnostics Holdings plc and confirms that it has agreed a different resolution to the requirement for one.. Read More →

The Company was informed that today, Christopher Mills, a non-executive director, completed the purchase of 5,970 ordinary shares. .. Read More →

TR-1: Standard form for notification of major holdings - December 2018.. Read More →

TR-1: Standard form for notification of major holdings.. Read More →

TR-1: Standard form for notification of major holdings.. Read More →

Renalytix AI plc announces that it was yesterday notified that on 6 November 2018 the following PDMR undertook a transaction in the ordinary shares of.. Read More →

Renalytix AI plc, a developer of artificial intelligence enabled clinical diagnostic solutions for kidney disease, announces the admission of its ordinary shares to trading on.. Read More →

Renalytix AI plc announces that, further to the announcement by EKF Diagnostics Holdings plc (“EKF”) on 31 October confirming that RenalytixAI’s had successfully raised £22.25.. Read More →

Today RenalytixAI announced a successful, conditional equity fundraising, having secured funding commitments via a placing and subscription of not less than £21 million. The Company.. Read More →

Renalytix AI plc announces that it has conditionally raised gross funds of a minimum of £21 million in connection with its previously announced equity fundraising.. Read More →

Further to the Company’s announcement on 4 July 2018 in relation to Renalytix AI plc (“Renalytix AI”), EKF announces that it intends to undertake further.. Read More →

Renalytix AI PLC to develop Artificial Intelligence solutions for early identification and management of kidney disease.. Read More →

Mount Sinai and Renalytix AI today have entered into an exclusive multi-year license and collaboration to commercialize artificial intelligence solutions to improve kidney disease detection,.. Read More →